-
公开(公告)号:US06462176B1
公开(公告)日:2002-10-08
申请号:US08928069
申请日:1997-09-11
申请人: Avi J. Ashkenazi
发明人: Avi J. Ashkenazi
IPC分类号: C07K1447
CPC分类号: C07K14/70578 , A61K38/00 , A61K2039/505 , C07K14/4747 , C07K16/2878 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要: Novel polypeptides, designated Apo-3, which are capable of stimulating or inducing apoptosis are provided. Compositions including Apo-3 chimeras, nucleic acid encoding Apo-3, and antibodies to Apo-3 are also provided.
摘要翻译: 提供了能够刺激或诱导细胞凋亡的新型多肽,称为Apo-3。 还提供了包含Apo-3嵌合体,编码Apo-3的核酸和Apo-3抗体的组合物。
-
公开(公告)号:US6046048A
公开(公告)日:2000-04-04
申请号:US780496
申请日:1997-01-08
IPC分类号: C07K14/705 , C07K16/28 , C12N5/16
CPC分类号: C07K14/70575 , C07K16/2875 , C07K2317/34
摘要: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
摘要翻译: 提供了诱导哺乳动物细胞凋亡的新型细胞因子,称为Apo-2配体。 Apo-2配体被认为是TNF细胞因子家族的成员。 还提供了包括Apo-2配体嵌合体,编码Apo-2配体的核酸和Apo-2配体的抗体的组合物。 进一步提供了使用Apo-2配体诱导细胞凋亡和治疗病理状况如癌症的方法。
-
公开(公告)号:US20120328603A1
公开(公告)日:2012-12-27
申请号:US13303638
申请日:2011-11-23
申请人: Avi J. Ashkenazi , Klaus W. Wagner
发明人: Avi J. Ashkenazi , Klaus W. Wagner
IPC分类号: C12Q1/68 , C40B30/04 , A61N5/10 , A61P37/00 , A61P35/00 , G01N33/574 , A61K39/395
CPC分类号: G01N33/573 , C07K16/2878 , C07K16/2896 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/57419 , G01N33/57438 , G01N33/57446 , G01N2333/91091 , G01N2333/91097 , G01N2510/00
摘要: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
摘要翻译: 提供检查哺乳动物组织或细胞样品中一种或多种生物标志物的表达的方法和试验。 根据所公开的方法和测定,检测一种或多种此类生物标志物的表达是预测或指示组织或细胞样品对凋亡诱导剂如Apo2L / TRAIL和抗DR5激动剂抗体敏感。 可以检查的某些生物标志物包括岩藻糖基转移酶,特别是岩藻糖基转移酶3(FUT3)和/或岩藻糖基转移酶6(FUT6)以及唾液酸基路易斯A和/或X抗原。 还提供了工具包和制品。
-
54.
公开(公告)号:US20120189573A1
公开(公告)日:2012-07-26
申请号:US13136490
申请日:2011-08-01
申请人: Avi J. Ashkenazi
发明人: Avi J. Ashkenazi
CPC分类号: A61K31/517 , A61K38/17 , C07K16/2878 , C12N5/0693 , C12N2501/11 , C12N2501/48 , A61K2300/00
摘要: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
摘要翻译: 提供了使用诸如Apo-2配体/ TRAIL多肽或死亡受体抗体的死亡受体配体和用于治疗病理状况如癌症的EGFR抑制剂的方法。 本发明的实施方案包括使用Apo2L / TRAIL或死亡受体抗体如DR5抗体和DR4抗体与EGFR抑制剂如Tarceva TM组合的方法。
-
公开(公告)号:US07855066B1
公开(公告)日:2010-12-21
申请号:US11528948
申请日:2006-09-28
申请人: Avi J. Ashkenazi , Sarah Hymowitz , Robert F. Kelley , Iphigenia Koumenis , Woon-Lam Susan Leung , Mark O'Connell , Roger Pai , Zahra Shahrokh , Laura Simmons
发明人: Avi J. Ashkenazi , Sarah Hymowitz , Robert F. Kelley , Iphigenia Koumenis , Woon-Lam Susan Leung , Mark O'Connell , Roger Pai , Zahra Shahrokh , Laura Simmons
CPC分类号: A61K9/19 , A61K9/0019 , A61K38/00 , A61K47/02 , C07K14/525 , C07K14/70575
摘要: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
摘要翻译: 提供使用二价金属离子制备Apo-2配体和Apo-2配体制剂的方法。 这种二价金属离子包括改善Apo-2配体三聚体形成和稳定性的锌和钴。 还提供了Apo-2配体的晶体结构,以及使用寡核苷酸定向突变鉴定的Apo-2配体变体多肽。
-
公开(公告)号:US20100158856A1
公开(公告)日:2010-06-24
申请号:US12589497
申请日:2009-10-23
申请人: Avi J. Ashkenazi , Klaus W. Wagner
发明人: Avi J. Ashkenazi , Klaus W. Wagner
CPC分类号: A61K38/1709 , C12Q1/48 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/573 , G01N33/57419 , G01N33/57438 , G01N33/57446 , G01N33/6863 , G01N33/6893 , G01N2333/91091 , G01N2510/00 , G01N2800/24
摘要: Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
摘要翻译: 提供检查哺乳动物组织或细胞样品中一种或多种生物标志物的表达的方法和试验。 根据所公开的方法和测定,检测一种或多种此类生物标志物的表达是预测或指示组织或细胞样品对凋亡诱导剂如Apo2L / TRAIL和抗DR5激动剂抗体敏感。 可以检查的某些生物标志物包括岩藻糖基转移酶,特别是岩藻糖基转移酶3(FUT3)和/或岩藻糖基转移酶6(FUT6)以及唾液酸基路易斯A和/或X抗原。 还提供了工具包和制品。
-
公开(公告)号:US20090186812A1
公开(公告)日:2009-07-23
申请号:US11528951
申请日:2006-09-28
申请人: Avi J. Ashkenazi , Ralph H. Schwall
发明人: Avi J. Ashkenazi , Ralph H. Schwall
IPC分类号: A61K38/16 , C07K14/00 , C12N15/11 , C12N15/00 , C12N5/06 , C12N1/21 , C12N1/19 , C12P21/02 , C08J3/00
CPC分类号: C07K14/70575 , A61K38/00 , C07K16/2875 , C07K2317/34 , C07K2317/73 , C07K2319/00
摘要: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
-
公开(公告)号:US20090175854A1
公开(公告)日:2009-07-09
申请号:US11662315
申请日:2005-09-07
申请人: Avi J. Ashkenazi
发明人: Avi J. Ashkenazi
IPC分类号: A61K39/395 , C12N5/06
CPC分类号: C07K16/2887 , A61K39/39558 , A61K2039/505 , A61K2039/507 , C07K16/2878 , C07K2317/24 , A61K2300/00
摘要: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.
摘要翻译: 提供了使用诸如Apo-2配体/ TRAIL多肽或死亡受体抗体的死亡受体配体的方法和用于治疗诸如癌症和免疫相关疾病的疾病的CD20抗体。 本发明的实施方案包括使用Apo2L / TRAIL或死亡受体抗体如DR5抗体和DR4抗体与CD20抗体组合的方法。
-
59.
公开(公告)号:US20090155247A1
公开(公告)日:2009-06-18
申请号:US11816451
申请日:2006-02-16
申请人: Avi J. Ashkenazi
发明人: Avi J. Ashkenazi
IPC分类号: A61K39/395 , C12N5/00 , A61K31/517 , A61P35/00
CPC分类号: A61K31/517 , A61K38/17 , C07K16/2878 , C12N5/0693 , C12N2501/11 , C12N2501/48 , A61K2300/00
摘要: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™.
摘要翻译: 提供了使用诸如Apo-2配体/ TRAIL多肽或死亡受体抗体的死亡受体配体和用于治疗病理状况如癌症的EGFR抑制剂的方法。 本发明的实施方案包括使用Apo2L / TRAIL或死亡受体抗体如DR5抗体和DR4抗体与EGFR抑制剂如Tarceva TM组合的方法。
-
公开(公告)号:US07449176B2
公开(公告)日:2008-11-11
申请号:US10193782
申请日:2002-07-12
IPC分类号: C07K14/435 , C07K14/715 , C07K14/57 , C07K16/24 , C07K19/00 , C07K16/18 , C07K16/00 , A61K38/00
CPC分类号: C07K14/57 , A61K38/00 , A61K2039/505 , C07K14/715 , C07K14/7156 , C07K16/00 , C07K16/241 , C07K16/249 , C07K19/00 , C07K2319/00 , C07K2319/30 , C07K2319/32
摘要: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.
摘要翻译: 本发明涉及通过施用干扰素-γ抑制剂预防或治疗炎性肠病的方法。 本发明还涉及可用于这种方法的药物组合物和双特异性分子。
-
-
-
-
-
-
-
-
-